Research Article| Volume 8, ISSUE 3, P165-170, January 2002

Download started.


The mitochondrial common deletion in Parkinson's disease and related movement disorders


      The mitochondrial 4977-bp common deletion has been reported in some studies to occur exclusively or with increased frequency in the midbrain of patients with Parkinson's disease (PD). Other studies could not confirm these results; rather, it was suggested that the mitochondrial common deletion is associated with aging in the midbrain and not PD. One possible explanation for these conflicting results is the difficulty in quantifying mitochondrial DNA deletions or mutations in the whole midbrain or substantia nigra (SN) while only a subset of midbrain neurons degenerate in PD. In addition, none of the studies has addressed the cell types with the common deletion within the midbrain. In this study we used in situ hybridization to detect the common deletion in sections of midbrain from patients with PD, multiple system atrophy-parkinsonian type (MSA-P), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), age-matched controls, and individuals of different ages. The results demonstrated that the mitochondrial common deletion accumulated primarily in neurons but not glia in both the SN and other midbrain regions. There was no significant difference in the number or distribution of neurons with the common deletion or the average of the mean densities (AMD) of staining with the common deletion in nigral neurons among patients with PD, MSA-P, PSP, DLB, or age-matched controls. In addition, there was no difference in the number or distribution of neurons with the common deletion in nigral neurons between any age group, although there was a tendency for the common deletion to increase in the non-nigral neurons in older patients. These data indicate that accumulation of the 4977-bp common deletion in mitochondrial DNA in midbrain occurred primarily in neurons, and by this cytological approach, it was not associated with nigral neurodegeneration in the common movement disorders or aging.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lowe J
        • Graham L
        • Leigh P.N
        Disorders of movement and system degeneration.
        in: Graham D.I Lantos P.L Greenfield's neuropathology. vol. II. Arnold, London1997: 281-366
        • Schapira A.H
        • Hartley A
        • Cleeter M.W
        • Cooper J.M
        Free radicals and mitochondrial dysfunction in Parkinson's disease.
        Biochem Soci Trans. 1993; 21: 367-370
        • Jenner P
        • Dexter D.T
        • Sian J
        • Schapira A.H
        • Marsden C.D
        Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease.
        Ann Neurol. 1992; 32: S82-S87
        • Di Monte D.A
        Mitochondrial DNA and Parkinson's disease.
        Neurology. 1991; 41 (discussion 42–3): 38-42
        • Benecke R
        • Strumper P
        • Weiss H
        Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes.
        Brain. 1993; 116: 1451-1463
        • Haas R.H
        • Nasirian F
        • Nakano K
        • Ward D
        • Pay M
        • Hill R
        • Shults C.W
        Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease.
        Ann Neurol. 1995; 37: 714-722
        • Swerdlow R.H
        • Parks J.K
        • Davis II, J.N
        • Cassarino D.S
        • Trimmer P.A
        • Currie L.J
        • Dougherty J
        • Bridges W.S
        • Bennett Jr., J.P
        • Wooten G.F
        • Parker W.D
        Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family.
        Ann Neurol. 1998; 44: 873-881
        • Ikebe S
        • Tanaka M
        • Ozawa T
        Point mutations of mitochondrial genome in Parkinson's disease.
        Brain Res. 1995; 28: 281-295
        • Swerdlow R.H
        • Parks J.K
        • Miller S.W
        • Tuttle J.B
        • Trimmer P.A
        • Sheehan J.P
        • Bennett Jr, J.P
        • Davis R.E
        • Parker Jr, W.D
        Origin and functional consequences of the complex I defect in Parkinson's disease.
        Ann Neurol. 1996; 40: 663-671
        • Veldman B.A
        • Wijn A.M
        • Knoers N
        • Praamstra P
        • Horstink M.W
        Genetic and environmental risk factors in Parkinson's disease.
        Clin Neurol Neurosurg. 1998; 100: 15-26
        • Marsden C.D
        • Olanow C.W
        The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality.
        Ann Neurol. 1998; 44: S189-S196
        • Langston J.W
        Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate.
        Ann Neurol. 1998; 44: S45-S52
        • Wallace D.C
        Mitochondrial genetics: a paradigm for aging and degenerative diseases?.
        Science. 1992; 256: 628-632
        • Clayton D.A
        Replication of animal mitochondrial DNA.
        Cell. 1982; 28: 693-705
        • Holt I.J
        • Harding A.E
        • Morgan-Hughes J.A
        Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies.
        Nature. 1988; 331: 717-719
        • Holt I.J
        • Harding A.E
        • Morgan-Hughes J.A
        Deletions of muscle mitochondrial DNA in mitochondrial myopathies: sequence analysis and possible mechanisms.
        Nucleic Acids Res. 1989; 17: 4465-4469
        • Ikebe S
        • Tanaka M
        • Ohno K
        • Sato W
        • Hattori K
        • Kondo T
        • Mizuno Y
        • Ozawa T
        Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence.
        Biochem Biophys Res Commun. 1990; 170: 1044-1048
        • Ozawa T
        • Tanaka M
        • Ikebe S
        • Ohno K
        • Kondo T
        • Mizuno Y
        Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis.
        Biochem Biophys Res Commun. 1990; 172: 483-489
        • Mann V.M
        • Cooper J.M
        • Schapira A.H
        Quantitation of a mitochondrial DNA deletion in Parkinson's disease.
        FEBS Lett. 1992; 299: 218-222
        • Kosel S
        • Egensperger R
        • Schnopp N.M
        • Graeber M.B
        The ‘common deletion’ is not increased in parkinsonian substantia nigra as shown by competitive polymerase chain reaction.
        Mov Disord. 1997; 12: 639-645
        • Nakamura N
        • Hattori N
        • Tanaka M
        • Mizuno Y
        Specific detection of deleted mitochondrial DNA by in situ hybridization using a chimera probe.
        Biochim Biophys Acta. 1996; 1308: 215-221
        • Hirai K
        • Aliev G
        • Nunomura A
        • Fujioka H
        • Russell R.L
        • Atwood C.S
        • Johnson A.B
        • Kress Y
        • Vinters H.V
        • Tabaton M
        • Shimohama S
        • Cash A.D
        • Siedlak S.L
        • Harris P.L
        • Jones P.K
        • Petersen R.B
        • Perry G
        • Smith M.A
        Mitochondrial abnormalities in Alzheimer's disease.
        J Neurosci. 2001; 21: 3017-3023
      1. Calne DB, editor. Neurodegenerative diseases. Philadelphia: W.B. Saunders, 1994. p. 545–82.

        • Langston J.W
        • Ballard P
        • Tetrud J.W
        • Irwin I
        Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
        Science. 1983; 219: 979-980
        • Desai V.G
        • Feuers R.J
        • Hart R.W
        • Ali S.F
        MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport.
        Brain Res. 1996; 715: 1-8
        • Przedborski S
        • Jackson-Lewis V
        Mechanisms of MPTP toxicity.
        Mov Disord. 1998; 13: 35-38
        • Zhang J
        • Perry P
        • Smith M.A
        • Robertson D
        • Olson S.J
        • Graham D.G
        • Montine T.J
        Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.
        Am J Pathol. 1999; 154: 1423-1429
        • Yoritaka A
        • Hattori N
        • Uchida K
        • Tanaka M
        • Stadtman E.R
        • Mizuno Y
        Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
        Proc Natl Acad Sci USA. 1996; 93: 2696-2701
        • Simon D.K
        • Pulst S.M
        • Sutton J.P
        • Browne S.E
        • Beal M.F
        • Johns D.R
        Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation.
        Neurology. 1999; 53: 1787-1793